You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePractolol
Accession NumberDB01297
TypeSmall Molecule
GroupsApproved
DescriptionA beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. [PubChem]
Structure
Thumb
Synonyms
(+-)-Practolol
1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol
4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide
N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
Practololum
Tocris-0831
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIISUG9176GRW
CAS number6673-35-4
WeightAverage: 266.3361
Monoisotopic: 266.16304258
Chemical FormulaC14H22N2O3
InChI KeyInChIKey=DURULFYMVIFBIR-UHFFFAOYSA-N
InChI
InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
IUPAC Name
N-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
SMILES
CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetanilides. These are organic compounds containing an acetamide group conjugated to a phenyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilides
Direct ParentAcetanilides
Alternative Parents
Substituents
  • N-arylamide
  • Acetanilide
  • Phenol ether
  • Alkyl aryl ether
  • Acetamide
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the emergency treatment of cardiac arrhythmias.
PharmacodynamicsPractolol is a beta-adrenergic receptor antagonist that has been used in the emergency treatment of cardiac arrhythmias. Beta blockers inhibit normal epinephrine-mediated sympathetic actions, but have minimal effect on resting subjects. That is, they reduce the effect of excitement/physical exertion on heart rate and force of contraction and dilation of blood vessels.
Mechanism of actionLike other beta-adrenergic antagonists, practolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, practolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Practolol Action PathwayDrug actionSMP00669
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9472
Blood Brain Barrier-0.8609
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.589
P-glycoprotein inhibitor INon-inhibitor0.8705
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.9484
CYP450 2C9 substrateNon-substrate0.781
CYP450 2D6 substrateNon-substrate0.5082
CYP450 3A4 substrateNon-substrate0.6487
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.6103
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9289
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9268
Ames testNon AMES toxic0.9153
CarcinogenicityNon-carcinogens0.8402
BiodegradationNot ready biodegradable0.9564
Rat acute toxicity1.9187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9917
hERG inhibition (predictor II)Non-inhibitor0.898
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point134-136 °CPhysProp
logP0.79HANSCH,C ET AL. (1995)
Caco2 permeability-6.05ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.49 mg/mLALOGPS
logP0.53ALOGPS
logP0.83ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.59 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity75.24 m3·mol-1ChemAxon
Polarizability30.39 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC07AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Practolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Practolol.
AcepromazineAcepromazine may increase the hypotensive activities of Practolol.
AcetohexamidePractolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Practolol is combined with Acetylcholine.
AcetyldigitoxinPractolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Practolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Practolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Practolol.
AlfuzosinPractolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Practolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Practolol.
AmiodaroneAmiodarone may increase the bradycardic activities of Practolol.
AmobarbitalThe serum concentration of Practolol can be decreased when it is combined with Amobarbital.
AmodiaquineThe metabolism of Practolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Practolol can be increased when it is combined with Amoxapine.
AntipyrineAntipyrine may decrease the antihypertensive activities of Practolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Practolol.
ApraclonidineApraclonidine may increase the atrioventricular blocking (AV block) activities of Practolol.
ApremilastApremilast may decrease the antihypertensive activities of Practolol.
ArecolineThe risk or severity of adverse effects can be increased when Practolol is combined with Arecoline.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Practolol.
AzelastineAzelastine may decrease the antihypertensive activities of Practolol.
BalsalazideBalsalazide may decrease the antihypertensive activities of Practolol.
BarbitalThe serum concentration of Practolol can be decreased when it is combined with Barbital.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Practolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.
BethanecholThe risk or severity of adverse effects can be increased when Practolol is combined with Bethanechol.
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Practolol.
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Practolol.
BromfenacBromfenac may decrease the antihypertensive activities of Practolol.
BromocriptinePractolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Practolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Practolol.
CabergolinePractolol may increase the vasoconstricting activities of Cabergoline.
CarbacholThe risk or severity of adverse effects can be increased when Practolol is combined with Carbachol.
CarprofenCarprofen may decrease the antihypertensive activities of Practolol.
CarvedilolPractolol may increase the orthostatic hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Practolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Practolol.
CevimelineThe risk or severity of adverse effects can be increased when Practolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Practolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Practolol.
ChlorpropamidePractolol may increase the hypoglycemic activities of Chlorpropamide.
ClomipramineThe serum concentration of Practolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Practolol.
ClonixinClonixin may decrease the antihypertensive activities of Practolol.
CoumaphosCoumaphos may increase the bradycardic activities of Practolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Practolol.
DapoxetineThe serum concentration of Practolol can be increased when it is combined with Dapoxetine.
DecamethoniumDecamethonium may increase the bradycardic activities of Practolol.
DemecariumDemecarium may increase the bradycardic activities of Practolol.
DeslanosidePractolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Practolol.
DichlorvosDichlorvos may increase the bradycardic activities of Practolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Practolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Practolol.
DigitoxinPractolol may increase the bradycardic activities of Digitoxin.
DigoxinPractolol may increase the bradycardic activities of Digoxin.
DihydroergotaminePractolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Practolol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Practolol.
DipyridamoleDipyridamole may increase the bradycardic activities of Practolol.
DisopyramideDisopyramide may increase the bradycardic activities of Practolol.
DonepezilDonepezil may increase the bradycardic activities of Practolol.
DoxazosinPractolol may increase the orthostatic hypotensive activities of Doxazosin.
DronedaroneDronedarone may increase the bradycardic activities of Practolol.
DroxicamDroxicam may decrease the antihypertensive activities of Practolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Practolol.
EchothiophateEchothiophate may increase the bradycardic activities of Practolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Practolol.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Practolol.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Practolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Practolol.
EpirizoleEpirizole may decrease the antihypertensive activities of Practolol.
Ergoloid mesylatePractolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovinePractolol may increase the vasoconstricting activities of Ergonovine.
ErgotaminePractolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Practolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Practolol.
EtodolacEtodolac may decrease the antihypertensive activities of Practolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Practolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Practolol.
EtoperidoneThe serum concentration of Practolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Practolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Practolol.
exisulindexisulind may decrease the antihypertensive activities of Practolol.
FenbufenFenbufen may decrease the antihypertensive activities of Practolol.
FenfluramineThe serum concentration of Practolol can be increased when it is combined with Fenfluramine.
FenoprofenFenoprofen may decrease the antihypertensive activities of Practolol.
FenthionFenthion may increase the bradycardic activities of Practolol.
FingolimodPractolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Practolol.
FlunixinFlunixin may decrease the antihypertensive activities of Practolol.
FluoxetineThe serum concentration of Practolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Practolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Practolol.
GalantamineGalantamine may increase the bradycardic activities of Practolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Practolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Practolol.
GlibornuridePractolol may increase the hypoglycemic activities of Glibornuride.
GliclazidePractolol may increase the hypoglycemic activities of Gliclazide.
GlimepiridePractolol may increase the hypoglycemic activities of Glimepiride.
GlipizidePractolol may increase the hypoglycemic activities of Glipizide.
GliquidonePractolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepidePractolol may increase the hypoglycemic activities of Glisoxepide.
GlyburidePractolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Practolol is combined with GTS-21.
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Practolol.
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Practolol.
HexobarbitalThe serum concentration of Practolol can be decreased when it is combined with Hexobarbital.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Practolol.
Huperzine AHuperzine A may increase the bradycardic activities of Practolol.
HydroxychloroquineThe metabolism of Practolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Practolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Practolol.
IcatibantIcatibant may decrease the antihypertensive activities of Practolol.
IndalpineThe serum concentration of Practolol can be increased when it is combined with Indalpine.
IndomethacinIndomethacin may decrease the antihypertensive activities of Practolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Practolol.
IndoraminPractolol may increase the orthostatic hypotensive activities of Indoramin.
Insulin PorkPractolol may increase the hypoglycemic activities of Insulin Pork.
IsoflurophateIsoflurophate may increase the bradycardic activities of Practolol.
IsoxicamIsoxicam may decrease the antihypertensive activities of Practolol.
KebuzoneKebuzone may decrease the antihypertensive activities of Practolol.
KetoprofenKetoprofen may decrease the antihypertensive activities of Practolol.
KetorolacKetorolac may decrease the antihypertensive activities of Practolol.
LabetalolPractolol may increase the orthostatic hypotensive activities of Labetalol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Practolol.
LevomilnacipranThe serum concentration of Practolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Practolol.
LobelineThe risk or severity of adverse effects can be increased when Practolol is combined with Lobeline.
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Practolol.
LornoxicamLornoxicam may decrease the antihypertensive activities of Practolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Practolol.
Lu AA21004The serum concentration of Practolol can be increased when it is combined with Lu AA21004.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Practolol.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Practolol.
MalathionMalathion may increase the bradycardic activities of Practolol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Practolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Practolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Practolol.
MefloquineMefloquine may increase the bradycardic activities of Practolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Practolol.
MemantineMemantine may increase the bradycardic activities of Practolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Practolol.
MesalazineMesalazine may decrease the antihypertensive activities of Practolol.
MesoridazineMesoridazine may increase the hypotensive activities of Practolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Practolol.
MethacholineThe risk or severity of adverse effects can be increased when Practolol is combined with Methacholine.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.
MethohexitalThe serum concentration of Practolol can be decreased when it is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Practolol.
Methylene blueMethylene blue may increase the hypotensive activities of Practolol.
MethylphenobarbitalThe serum concentration of Practolol can be decreased when it is combined with Methylphenobarbital.
MidodrinePractolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Practolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Practolol.
MoricizineMoricizine may increase the hypotensive activities of Practolol.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Practolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Practolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Practolol.
NaftifineNaftifine may decrease the antihypertensive activities of Practolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Practolol.
NaproxenNaproxen may decrease the antihypertensive activities of Practolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Practolol.
NeostigmineNeostigmine may increase the bradycardic activities of Practolol.
NepafenacNepafenac may decrease the antihypertensive activities of Practolol.
NicotineThe risk or severity of adverse effects can be increased when Practolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Practolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Practolol.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Practolol.
NimesulideNimesulide may decrease the antihypertensive activities of Practolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Practolol.
OlanzapineThe serum concentration of Practolol can be increased when it is combined with Olanzapine.
OlopatadineOlopatadine may decrease the antihypertensive activities of Practolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Practolol.
OrgoteinOrgotein may decrease the antihypertensive activities of Practolol.
OuabainPractolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Practolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Practolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Practolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Practolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Practolol.
ParoxetineThe serum concentration of Practolol can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Practolol can be decreased when it is combined with Pentobarbital.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Practolol.
PerphenazinePerphenazine may increase the hypotensive activities of Practolol.
PhenobarbitalThe serum concentration of Practolol can be decreased when it is combined with Phenobarbital.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Practolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Practolol.
PhysostigminePhysostigmine may increase the bradycardic activities of Practolol.
PilocarpineThe risk or severity of adverse effects can be increased when Practolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Practolol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Practolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Practolol.
PrazosinPractolol may increase the orthostatic hypotensive activities of Prazosin.
PrimaquineThe metabolism of Practolol can be decreased when combined with Primaquine.
PrimidoneThe serum concentration of Practolol can be decreased when it is combined with Primidone.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Practolol.
PromazinePromazine may increase the hypotensive activities of Practolol.
PromethazinePromethazine may increase the hypotensive activities of Practolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Practolol.
PropafenoneThe serum concentration of Practolol can be increased when it is combined with Propafenone.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Practolol.
PTC299PTC299 may decrease the antihypertensive activities of Practolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Practolol.
RegorafenibRegorafenib may increase the bradycardic activities of Practolol.
ReserpineReserpine may increase the hypotensive activities of Practolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Practolol.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Practolol.
RivastigmineRivastigmine may increase the bradycardic activities of Practolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Practolol.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Practolol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Practolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Practolol.
SalsalateSalsalate may decrease the antihypertensive activities of Practolol.
SecobarbitalThe serum concentration of Practolol can be decreased when it is combined with Secobarbital.
SeratrodastSeratrodast may decrease the antihypertensive activities of Practolol.
SertralineThe serum concentration of Practolol can be increased when it is combined with Sertraline.
SilodosinPractolol may increase the orthostatic hypotensive activities of Silodosin.
SRT501SRT501 may decrease the antihypertensive activities of Practolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Practolol.
SulindacSulindac may decrease the antihypertensive activities of Practolol.
SuprofenSuprofen may decrease the antihypertensive activities of Practolol.
TacrineTacrine may increase the bradycardic activities of Practolol.
TamsulosinPractolol may increase the orthostatic hypotensive activities of Tamsulosin.
TenoxicamTenoxicam may decrease the antihypertensive activities of Practolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Practolol.
TerazosinPractolol may increase the orthostatic hypotensive activities of Terazosin.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Practolol.
ThiamylalThe serum concentration of Practolol can be decreased when it is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Practolol.
ThiopentalThe serum concentration of Practolol can be decreased when it is combined with Thiopental.
ThioridazineThioridazine may increase the hypotensive activities of Practolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Practolol.
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Practolol.
TolazamidePractolol may increase the hypoglycemic activities of Tolazamide.
TolbutamidePractolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Practolol.
TolmetinTolmetin may decrease the antihypertensive activities of Practolol.
TranilastTranilast may decrease the antihypertensive activities of Practolol.
TrazodoneThe serum concentration of Practolol can be increased when it is combined with Trazodone.
TrichlorfonTrichlorfon may increase the bradycardic activities of Practolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Practolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Practolol.
TrimazosinPractolol may increase the orthostatic hypotensive activities of Trimazosin.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Practolol.
TubocurarineTubocurarine may increase the bradycardic activities of Practolol.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Practolol.
VareniclineThe risk or severity of adverse effects can be increased when Practolol is combined with Varenicline.
VilazodoneThe serum concentration of Practolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Practolol can be increased when it is combined with Vortioxetine.
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Practolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Practolol.
ZileutonZileuton may decrease the antihypertensive activities of Practolol.
ZimelidineThe serum concentration of Practolol can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may decrease the antihypertensive activities of Practolol.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880 ]
  2. Keyrilainen O, Uusitalo A: A comparative study of three beta 1-adrenoreceptor blocking drugs with different degree of intrinsic stimulating activity (metoprolol, practolol and H 87/07) in patients with angina pectoris. Ann Clin Res. 1978 Aug;10(4):185-90. [PubMed:30388 ]
  3. Saarnivaara L, Lindgren L, Hynynen M: Effects of practolol and metoprolol on QT interval, heart rate and arterial pressure during induction of anaesthesia. Acta Anaesthesiol Scand. 1984 Dec;28(6):644-8. [PubMed:6524278 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Buxton IL, Brunton LL: Direct analysis of beta-adrenergic receptor subtypes on intact adult ventricular myocytes of the rat. Circ Res. 1985 Jan;56(1):126-32. [PubMed:2857116 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 08:19 / Updated on August 17, 2016 12:23